Anthony Insogna is chair of Jones Day's global IP practice and is a leading pharmaceutical and biotechnology patent lawyer as recognized by Chambers, Legal 500, and his peers. He has 25 years of experience enforcing and defending patent portfolios for some of the world's most successful pharmaceutical and biotech therapeutics. Anthony's experience includes domestic and foreign litigation, post-grant proceedings including Inter Partes Review (IPR), patent portfolio strategy, oppositions, interferences, invalidation proceedings, and transactions for products including Abraxane®, Allegra®, Brovana®, Clarinex®, Clofar®, Embospheres®, Ethyol®, Focalin®, Focalin XR®, HepaSpheres®, Istodax®, Kuvan®, Lunesta®, Nithiodote®, Otezla®, Pristiq®, Pomalyst®, Relafen®, Revlimid®, Rezield™, Ritalin LA®, Synagis®, Thalomid®, Tyzeka®, Vidaza®, Xyrem®, Zytiga®, and others as well as many product candidates currently in clinical trials. Currently, he is representing Acadia with pimavanserin for CNS disorders, Puma with neratinib for cancer, Sunesis with vosaroxin for leukemia, Celgene with CC-122 for cancer and CC-220 for inflammation, Akebia with AKB-6548 for CKD anemia, and Ambit Biosciences with quizartinib, among others.In addition to U.S. and foreign patent litigation, Anthony has significant experience with European oppositions and with Chinese, Canadian, and Australian invalidation proceedings. He also has significant experience with the drug approval process under the U.S. FDA laws and more than 25 years of experience with the Hatch-Waxman Act. He regularly advises on IP issues attendant to M&A, transactions, and financing for life sciences companies.